Valneva SE (VALN)
NASDAQ: VALN · Real-Time Price · USD
6.18
+0.03 (0.49%)
At close: Apr 10, 2026, 4:00 PM EDT
6.06
-0.12 (-1.94%)
After-hours: Apr 10, 2026, 6:06 PM EDT
Valneva SE Employees
Valneva SE had 674 employees as of December 31, 2025. The number of employees decreased by 39 or -5.47% compared to the previous year.
Employees
674
Change
-39
Growth
-5.47%
Revenue / Employee
$304,260
Profits / Employee
-$200,667
Market Cap
545.59M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 674 | -39 | -5.47% |
| Jun 30, 2025 | 700 | - | - |
| Dec 31, 2024 | 713 | 37 | 5.47% |
| Dec 31, 2023 | 676 | -43 | -5.98% |
| Dec 31, 2022 | 719 | -43 | -5.64% |
| Dec 31, 2021 | 762 | 262 | 52.40% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| MiMedx Group | 808 |
| Lyell Immunopharma | 300 |
| CorMedix | 191 |
| Rigel Pharmaceuticals | 174 |
| Kyverna Therapeutics | 130 |
| Upstream Bio | 75 |
| Aclaris Therapeutics | 73 |
| Prothena Corporation | 67 |
VALN News
- 2 days ago - INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALN - PRNewsWire
- 4 days ago - INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALN - GlobeNewsWire
- 9 days ago - Declaration of shares and voting rights of Valneva SE – March 2026 - GlobeNewsWire
- 16 days ago - Valneva to Participate in Multiple Events at the 26th World Vaccine Congress in Washington DC - GlobeNewsWire
- 18 days ago - INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Valneva SE – VALN - GlobeNewsWire
- 19 days ago - Valneva (VALN) Maintains Buy Rating Despite Vaccine Trial Challenges - GuruFocus
- 19 days ago - An experimental Lyme disease vaccine from Pfizer and Valneva was effective at preventing the tick-borne disease in a new clinical trial but the findings aren't conclusive - WSJ
- 19 days ago - Lyme disease vaccine 70 percent effective: Pfizer - The Hill